Synergy Pharmaceuticals Appoints Gail M. Comer, M.D. as Chief Medical Officer
02 Maio 2012 - 5:00AM
Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU)
(Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal
disorders and diseases, announced today the appointment of Gail M.
Comer, M. D. as Chief Medical Officer, effective May 14, 2012. In
this newly created position, Dr. Comer will report directly to
President and Chief Executive Officer, Gary S. Jacob, Ph.D., and
will be responsible for guiding Synergy's clinical programs,
including the ongoing Phase II/III study of plecanatide, the
Company's leading drug candidate.
"Dr. Comer is a tremendous addition to our management team, and
I am very pleased to welcome her to Synergy," said Dr. Jacob. "Dr.
Comer has an extremely strong medical and academic background,
along with extensive industry experience in clinical research."
Dr. Comer, a board-certified gastroenterologist and
hepatologist, has more than 14 years of experience in the
pharmaceutical industry, having spent 7 years at Abbott
Laboratories as a Medical Director, six years in clinical
development at Wyeth Research as Senior Medical Director, and most
recently as Senior Director of the BioTherapeutics Research Unit at
Pfizer. While at Wyeth, Dr. Comer was Medical Research Leader in
Gastroenterology, and more recently, while at Pfizer, was Clinical
Lead for multiple biologic compounds in early development in
inflammatory bowel disease. Dr. Comer was an Associate
Professor of Clinical Medicine at The State University of New York
at Stony Brook prior to joining the pharmaceutical industry.
"Synergy's GC-C receptor agonist program represents an
innovative and exciting technology platform that I believe offers
great potential for the treatment of patients with GI disorders and
diseases," said Dr. Comer. "I believe the depth of my experience in
clinical development specifically in gastroenterology will play a
pivotal role in maximizing Synergy's clinical potential with these
drugs, and am very pleased and excited to be joining Synergy at
this opportune time."
About Synergy Pharmaceuticals, Inc.
Synergy is a biopharmaceutical company focused on the
development of new drugs to treat gastrointestinal disorders and
diseases. Synergy's lead proprietary drug candidate plecanatide is
a synthetic analog of the human gastrointestinal hormone
uroguanylin, and functions by activating the guanylate cyclase C
receptor on epithelial cells of the GI tract. Synergy completed a
Phase I study of plecanatide in healthy volunteers and a Phase IIa
clinical trial in CIC patients. In October, 2011, Synergy initiated
dosing of patients in a major Phase II/III clinical trial of
plecanatide to treat chronic idiopathic constipation. Plecanatide
is also being developed to treat IBS-C, with the first trial in
IBS-C patients planned for 2H2012. Synergy's second GC-C agonist
SP-333 is currently in pre-clinical development to treat
inflammatory bowel diseases. More information is available at
http://www.synergypharma.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as "anticipate," "planned," "believe,"
"forecast," "estimated," "expected," and "intend," among others.
These forward-looking statements are based on Synergy's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, substantial
competition; our ability to continue as a going concern; our need
for additional financing; uncertainties of patent protection and
litigation; uncertainties of government or third party payer
reimbursement; limited sales and marketing efforts and dependence
upon third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations. As
with any pharmaceutical under development, there are significant
risks in the development, regulatory approval and commercialization
of new products. There are no guarantees that future clinical
trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for
any indication or prove to be commercially successful. Synergy does
not undertake any obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in Synergy's Form 10-K for the year ended December 31,
2011 and other periodic reports filed with the Securities and
Exchange Commission.
CONTACT: Investor Contact Information:
Danielle Spangler
The Trout Group
synergy@troutgroup.com
(646) 378-2924
Synergy Pharmaceuticals - Warrants (NASDAQ:SGYPW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Synergy Pharmaceuticals - Warrants (NASDAQ:SGYPW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024